Cohance Lifesciences

Cohance integrates payload-linker chemistry, bioconjugation, and GMP manufacturing for ADCs. Antibody drug conjugate services from discovery to clinic with NJ Bio.

Explore Cohance CDMO services for small molecule APIs, ADCs, and nucleoside & phosphoramidite development, from route scouting to commercial supply.

Explore Cohance Lifesciences’ generic API portfolio featuring DMF-registered and CEP-listed molecules for regulated markets and global pharmaceutical companies.

Cohance provide nucleic acid chemistry services for pharmaceutical development, including oligonucleotide synthesis, process development, analytical testing, and manufacturing.

The page discusses Cohance’s expertise in antibody drug conjugates (ADCs) and cancer’s global impact on healthcare systems.

The page examines how oligonucleotide manufacturing shifts focus from the molecule to production capabilities as programs advance.

The page offers brochures, videos, and presentations showcasing Cohance’s capabilities in development and manufacturing.

Catch the latest media coverage and news featuring Cohance Lifesciences. A leading pharma CDMO and CRDMO partner in APIs, ADCs and nucleic acid chemistry.

The page provides official press releases on Cohance’s business milestones and regulatory updates.

Cohance fosters innovation through collaboration, career growth, and purpose-driven work across its teams.

Abhimanyu Ojha serves as Chief Financial Officer at Cohance Lifesciences, overseeing global finance and strategy.

The page introduces Cohance Lifesciences’ leadership team, which guides its global CDMO operations.

Umang Vohra was appointed Chairman and Group CEO of Cohance Lifesciences in May 2026.

Pankaj Patwari was appointed a Non-Executive Director of Cohance in September 2023.

Cohance Lifesciences is a scientist-led CRDMO spanning API, ADC, and nucleic acid chemistry. Backed by 20+ facilities and a pharma innovation heritage since 2003.

The page lists Cohance’s corporate policies, including sustainability, ethics, and governance frameworks.

Corporate info

Cohance will exhibit generic APIs, pellets, and dosage forms at CPHI Milan 2026, highlighting scalable supply and regulatory expertise.

The page directs API, CDMO, and pharmaceutical business inquiries to Cohance’s contact team.

Cohance invites meetings at CPHI Milan 2026 (Stand 6C39) to discuss pharmaceutical development and manufacturing.

Cohance provides integrated CDMO services for small molecules, ADCs, and nucleic acid chemistry from development to commercial scale.

The page offers brochures, ISO certificates, and business details, including governance and committee compositions.